Skip to main content
Amylyx Pharmaceuticals, Inc. logo

Amylyx Pharmaceuticals, Inc. — Investor Relations & Filings

Ticker · AMLX ISIN · US0321085088 US Manufacturing
Open in API
Filings indexed 384 across all filing types
Latest filing 2022-05-05 Director's Dealing
Country US United States of America
Listing US AMLX

About Amylyx Pharmaceuticals, Inc.

https://www.amylyx.com/

Amylyx Pharmaceuticals, Inc. is a biopharmaceutical company focused on the discovery and development of novel therapies for neurodegenerative diseases and other conditions with high unmet medical needs. The company's primary therapeutic candidate was AMX0035 for the treatment of amyotrophic lateral sclerosis (ALS). In April 2024, following the results of a Phase 3 clinical trial, Amylyx announced it would voluntarily withdraw the marketing authorizations for AMX0035 in the U.S. and Canada. The company is advancing a pipeline of other investigational therapies, utilizing a modality-agnostic approach to match treatments to diseases based on mechanistic rationale and rigorous scientific data.

Recent filings

Filing Released Lang Actions
FORM 4 SUBMISSION
Director's Dealing
2022-05-05 English
FORM 3 SUBMISSION
Director's Dealing
2022-05-05 English
DEFA14A
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a Schedule 14A filing, which is a proxy statement or related materials filed pursuant to the Securities Exchange Act of 1934. It includes information about the annual stockholders' meeting, proposals to be voted on, and instructions for accessing proxy materials and voting. The document is titled 'Definitive Additional Materials' related to the proxy statement, and it does not contain the full proxy statement itself but rather additional materials or notices related to the proxy process. This fits the category of Proxy Solicitation & Information Statement (PSI), which includes materials sent to shareholders to provide information and request votes for meetings. The document length is about 5,011 characters, which is consistent with a detailed proxy solicitation material rather than a brief notice or a full annual report. Therefore, the appropriate classification is PSI with high confidence.
2022-04-29 English
DEF 14A
Proxy Solicitation & Information Statement
2022-04-29 English
10-K
Annual Report FY 2021
2022-03-31 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K current report filed with the SEC, dated March 30, 2022, by Amylyx Pharmaceuticals, Inc. It announces the issuance of a press release containing financial results for the year ended December 31, 2021. The document explicitly states that the press release is furnished as an exhibit and incorporated by reference, and the 8-K itself does not contain detailed financial statements or substantive financial data. The document length is 3504 characters, which is relatively short and consistent with an announcement rather than a full report. According to the 'Menu vs Meal' rule, this is an announcement of financial results, not the financial report itself. Therefore, the appropriate classification is Earnings Release (ER), which covers initial announcements of quarterly or periodical financial results with key highlights only.
2022-03-31 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.